Dr. Brophy is a Clinical Investigator at the Children’s Hospital of Eastern Ontario (CHEO) Research Institute, the Medical Director of the CHEO HIV Clinic, a Physician at the Division of Infectious Diseases in the Department of Pediatrics, an associate professor in the Department of Pediatrics at the University of Ottawa, and the past (2012–2016) and current (2020–present) chair of the Canadian Pediatric & Perinatal HIV/AIDS Research Group. He also works part-time as a Pediatric HIV Clinical Advisor to the Clinton Health Access Initiative supporting pediatric HIV care and treatment in Africa and Southeast Asia. In 2019, he was appointed as the Co-lead of the CTN’s Clinical Care and Management Core with Dr. Mona Loutfy.
Dr. Brophy completed his medical degree and his pediatrics residency at Memorial University in Newfoundland, and his infectious diseases fellowship and CTN Postdoctoral Fellowship (2005–2007) at the University of Toronto. As part of his CTN fellowship, he also earned a master’s degree in health research methodology from McMaster University, and a Diploma of Tropical Medicine.
His research interests include the epidemiology and clinical care of HIV in pediatrics within Canada and globally, as well as the investigation of long-term toxicities that are related to antiretroviral therapy (ART) and HIV.
Dr. Brophy is involved with a number of studies with the CTN. He is a co-principal investigator of CTN 281, which focuses on the early use of ART in vertically transmitted cases of HIV, as well as of CTN 315, which will investigate neurocognition and neuroanatomical effects of in utero antiretroviral exposure on children who are HIV-exposed but uninfected. He is also the principal investigator for CTNPT 003, a pilot study that aims to better understand the effects of tenofovir and zidovudine on infants’ health. He is a co-investigator for CTN 236, CTN 262, and CTN 277. Dr. Brophy has mentored many trainees including two CTN postdoctoral fellows: Dr. Michael Clark (2012–2013) and Dr. Nancy Nashid (2017–2019).